Relief Therapeutics Advances Pipeline and Explores AI-driven Expansion

RELIEF THERAPEUTICS Holding ( (CH:RLF) ) just unveiled an update.

Relief Therapeutics has released its 2025 half-year report, highlighting significant progress in its pipeline and corporate initiatives. The company has advanced its lead wound care candidate RLF-TD011 and is preparing for a pivotal trial of its next-generation liquid sapropterin formulation, RLF-OD032, for phenylketonuria. With cash reserves projected to last into late 2026, Relief is also exploring a business combination with NeuroX to establish an AI-driven health tech company.

More about RELIEF THERAPEUTICS Holding

Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company focused on delivering innovative treatments for rare and debilitating diseases. With expertise in drug delivery systems and drug repurposing, the company targets unmet medical needs in dermatological, metabolic, and respiratory conditions. Headquartered in Geneva, it is listed on the SIX Swiss Exchange and quoted in the U.S. on OTCQB.

Average Trading Volume: 40,104

Technical Sentiment Signal: Sell

Current Market Cap: CHF32.19M

For detailed information about RLF stock, go to TipRanks’ Stock Analysis page.